PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (...
April 24 2018 - 1:00AM
REGULATED INFORMATION
GHENT, Belgium,
24 April 2018 - Ablynx [Euronext Brussels and
Nasdaq: ABLX] today announced, in accordance with Article 14 of
the Belgian Law of 2 May 2007 regarding the publication of major
shareholdings in issuers whose securities are admitted to trading
on a regulated market (the "Transparency Law"), that it received
two notifications of shareholdings from UBS Group AG on 18 April
2018.
UBS Group AG (taking into account
the holdings of its subsidiary undertakings) has notified Ablynx
that it has downward crossed the 3% threshold of voting rights held
directly by controlled undertakings on 12 April 2018 and upward
crossed this threshold again on 13 April 2018.
UBS Group AG now holds 5,528,330 voting securities of Ablynx,
representing 7.35% of the current 75,253,667 outstanding voting
rights of Ablynx (versus 7.21% notified previously on 10 April
2018).
The latest notification contains
the following information:
-
Reason for the
notification:
-
Notification by: a parent
undertaking or a controlling person
-
Persons subject to the
notification requirement: USB Group AG
-
Transaction date: 13 April
2018
-
Threshold that is crossed:
3%
-
Denominator:
75,253,667
-
Details of the
notification:
Name of select subsidiaries of UBS |
% of voting rights |
% of voting rights held through financial
instruments* |
Total of both |
UBS
AG |
0.20% |
0.13%1 /
2.72%2 /
0.10%3 |
3.15% |
UBS Asset
Management Trust Company |
0.00% |
|
0.00% |
UBS Fund
Management (Luxembourg) S.A. |
0.03% |
|
0.03% |
UBS Fund
Management (Switzerland) AG |
0.03% |
|
0.03% |
UBS Hedge
Fund Solutions LLC |
0.44% |
|
0.44% |
UBS
Limited |
0.60% |
|
0.60% |
UBS
O'Connor LLC |
1.35% |
|
1.35% |
UBS
Switzerland AG |
0.84% |
0.13%1 /
0.11%2 /
0.67%2 |
1.75% |
UBS
Securities LLC |
|
0.00%3 |
0.00% |
TOTAL |
3.48% |
3.86% |
7.35% |
* Type of
financial instrument: 1'Right to
recall lent shares' and 2'Right to
substitute shares delivered as collateral' and 3'Depository
Receipt'
-
Chain of controlled
undertakings through which the holding is effectively being
held: Please see the full chain of control in the Transparency
Notification.
-
Additional information: The
disclosure obligation arose due to the total indirect holdings in
voting rights of UBS Group AG, held directly by controlled
undertakings going above 3% on 13 April 2018.
More information is available in
the transparency notification. A full version of the transparency
notifications is available on Ablynx website, under the section
Investors.
The articles of the association of
Ablynx NV provide for shareholders notification threshold of 3%, 5%
or a multiple of 5% of the total number of existing voting
rights.
About
Ablynx
Ablynx is a biopharmaceutical
company engaged in the development of Nanobodies, proprietary
therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with
some of the features of small-molecule drugs. Ablynx is dedicated
to creating new medicines which will make a real difference to
society. Today, the Company has more than 45 proprietary and
partnered programmes in development in various therapeutic areas
including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple
pharmaceutical companies including AbbVie; Boehringer Ingelheim;
Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA;
Merck KGaA; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The
Company is headquartered in Ghent, Belgium. More information can be
found on www.ablynx.com.
On 29 January 2018, Sanofi made an
offer to acquire all of Ablynx's outstanding ordinary shares
(including shares represented by American Depository Shares (ADSs),
warrants and convertible bonds) at a price of €45 per share, which
represents an aggregate equity value of approximately €3.9 billion.
The proposed transaction was unanimously approved by both the
Sanofi and Ablynx Board of Directors. The initial tender offer
commenced on 4 April 2018 and will expire on 4 May 2018, subject to
extension. Sanofi has published an offer document in which it set
out the full details of its tender offer, and the Board of
Directors of Ablynx published a response memorandum ('memorie van
antwoord'), in which it set out its position on the tender
offer.
For more
information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media
relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx@consilium-comms.com
Joele Frank,
Wilkinson Brimmer Katcher
Dan Katcher or Joseph Sala
t: +1 212-355-4449
pdf version of the press
release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Ablynx via Globenewswire
Ablynx NV (NASDAQ:ABLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ablynx NV (NASDAQ:ABLX)
Historical Stock Chart
From Apr 2023 to Apr 2024